ReST Therapeutics is developing transformative therapies for patients with significant unmet needs in Psychiatry and Neurodegeneration.
Our lead program, RST-01, will disrupt the existing PTSD treatment paradigm, focusing on early intervention in the aftermath of a traumatic event and a patient-centric clinical strategy. RST-01 targets specific NMDA receptors sub-types, critical to memory consolidation.
Pre-clinical testing has shown drastic reductions in fear, anxiety and depression, as well as the restoration of cognitive function.
Finally, reduced neuroinflammation in neurodegenerative models paves the way for an extended development portfolio focusing on restoring the quality of lives of those affected by these debilitating diseases.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 101 College St, New Haven,connecticut 06510,united States
- Industry
- Biotechnology
- Website
- http://www.rest-therapeutics.com
- HQ
- New Haven, Connecticut
Rest Therapeutics Questions
Rest Therapeutics's website is http://www.rest-therapeutics.com
Rest Therapeutics's LinkedIn profile is https://www.linkedin.com/company/rest-therapeutics
Rest Therapeutics has
10 employees.
View email and phone details for 10
employees at Rest Therapeutics.
Rest Therapeutics's industry is
Biotechnology
Rest Therapeutics's top competitors are
Igyxos,
Tribun Health,
Nanology,
Theremia,
Orixha,
Inside Therapeutics (Insidetx),
Lyv,
Laboratoires Kôl,
Klineo,
Ronoma.
Rest Therapeutics's categories are Biotechnology
Rest Therapeutics's founding year is 2020
